Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocyte leukemia

Massimo Breccia, Giuseppe Cimino, Daniela Diverio, Fabiana Gentilini, Franco Mandelli, Francesco Lo Coco

Research output: Contribution to journalArticle

Abstract

We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m2) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.

Original languageEnglish
Pages (from-to)1273-1274
Number of pages2
JournalHaematologica
Volume92
Issue number9
DOIs
Publication statusPublished - Sep 2007

    Fingerprint

Keywords

  • Acute promyelocytic leukemia
  • Gentuzumab ozogamicin
  • Molecular relapse

ASJC Scopus subject areas

  • Hematology

Cite this